It will be interesting to see what value the market will bring to pbt2 possibly going back into the clinic in the near future - given the fact it has been completely priced out but has had 10 years of development behind it.
Bear in mind, the last line of defence drugs like colistin and carbapanem are having issues fighting new strains of bacteria which are showing more resistance to them. The fact that pbt2/zinc can be used in conjunction with these already approved drugs should have a high commercial value.
Ann: New commercial opportunity for PBT2, page-15
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(11.1%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $4.263K | 916.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 58 | 69165915 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 38212524 | 21 |
View Market Depth
| Last trade - 15.11pm 05/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |